Nephros, Inc. logo

Nephros, Inc.

NEPH

NASDAQHealthcareMedical - Instruments & Supplies

Latest quote

$4.15

−$0.325 · -7.38%

Aug 21, 3:55 PM ET

NEPH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

76

Undervalued

Momentum

36

Weakening

Sentiment

68

Bullish

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Robert Banks
Listed since
Sep 21, 2004
Employees
36

Market position

Volume
100.71K
4.99× average
Average volume
20.17K
Average daily volume
Market cap
44.29M USD
Beta
1.53
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
25.39×
P/B (TTM)
3.7×
P/S (TTM)
2.14×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
60.31%
Operating margin
7.92%
Net margin
8.38%

Financial health

Debt / equity
0.07×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%21%-33%-88%Gross margin, FY2021: 55.13%Gross margin, FY2022: 47.43%Gross margin, FY2023: 59.03%Gross margin, FY2024: 61.59%Gross margin, FY2025: 61.13%Operating margin, FY2021: -31.83%Operating margin, FY2022: -43.46%Operating margin, FY2023: -11.19%Operating margin, FY2024: 0.04%Operating margin, FY2025: 6.10%Net margin, FY2021: -40.20%Net margin, FY2022: -74.01%Net margin, FY2023: -11.06%Net margin, FY2024: 0.52%Net margin, FY2025: 6.35%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.13%. Gross margin FY2022 47.43%. Gross margin FY2023 59.03%. Gross margin FY2024 61.59%. Gross margin FY2025 61.13%. Operating margin FY2021 -31.83%. Operating margin FY2022 -43.46%. Operating margin FY2023 -11.19%. Operating margin FY2024 0.04%. Operating margin FY2025 6.10%. Net margin FY2021 -40.20%. Net margin FY2022 -74.01%. Net margin FY2023 -11.06%. Net margin FY2024 0.52%. Net margin FY2025 6.35%.

Income trends

Revenue

18.79M USD+32.67%

Operating income

1.15M USD+19000.00%

Net income

1.19M USD+1513.51%
Income trends across reported periods21.41M USD10.94M USD469.3K USD−10M USDRevenue, FY2021: 10.22M USDRevenue, FY2022: 9.98M USDRevenue, FY2023: 14.24M USDRevenue, FY2024: 14.16M USDRevenue, FY2025: 18.79M USDOperating income, FY2021: −3.25M USDOperating income, FY2022: −4.34M USDOperating income, FY2023: −1.59M USDOperating income, FY2024: 6K USDOperating income, FY2025: 1.15M USDNet income, FY2021: −4.11M USDNet income, FY2022: −7.38M USDNet income, FY2023: −1.58M USDNet income, FY2024: 74K USDNet income, FY2025: 1.19M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 10.22M USD. Revenue FY2022 9.98M USD. Revenue FY2023 14.24M USD. Revenue FY2024 14.16M USD. Revenue FY2025 18.79M USD. Operating income FY2021 −3.25M USD. Operating income FY2022 −4.34M USD. Operating income FY2023 −1.59M USD. Operating income FY2024 6K USD. Operating income FY2025 1.15M USD. Net income FY2021 −4.11M USD. Net income FY2022 −7.38M USD. Net income FY2023 −1.58M USD. Net income FY2024 74K USD. Net income FY2025 1.19M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue18.79M USD14.16M USD14.24M USD9.98M USD10.22M USD
Cost of goods sold7.3M USD5.44M USD5.83M USD5.24M USD4.58M USD
Gross profit11.49M USD8.72M USD8.41M USD4.73M USD5.63M USD
Research and development1.34M USD906K USD873K USD1.26M USD1.5M USD
Selling, general, and administrative9M USD7.68M USD8.91M USD7.59M USD7.2M USD
Operating expenses10.34M USD8.72M USD10M USD9.07M USD8.89M USD
Interest income139K USD94K USD64K USD14K USD10K USD
Interest expense1K USD1K USD2K USD20K USD41K USD
Depreciation and amortization140K USD137K USD214K USD571K USD252K USD
Operating income1.15M USD6K USD−1.59M USD−4.34M USD−3.25M USD
Net income1.19M USD74K USD−1.58M USD−7.38M USD−4.11M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$4.00

1.96% downside
Past 12 months12-month forecastHigh $4.00Average $4.00Low $4.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Stock split

Effective Jul 10, 2019

1:9

Stock split

Effective Mar 17, 2011

1:20

NEPH peers

ETFs holding NEPH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research NEPH

research.disclaimer